Cubist Pharmaceuticals Inc news

   Watch this stock
Showing stories 1 - 10 of about 89   

Articles published

CBST 63.93 +0.74 (1.17%)
price chart
What's Next for Cubist Pharmaceuticals Inc. and Durata Therapeutics, Inc.?
Cubist Pharmaceuticals (NASDAQ: CBST ) and Durata Therapeutics (NASDAQ: DRTX ) both won this week with nods by the FDA's advisory panels on each company's antibacterial agents. In two unanimous votes, the FDA panels agreed on the safety and ...
Related articles »  
Cubist Pharmaceuticals Inc.: Cubist to Announce First Quarter 2014 Financial ...
LEXINGTON, Mass.--(BUSINESS WIRE)-- Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) will issue its first quarter 2014 financial results at 4:00 p.m.
Active Movers - Organovo Holdings Inc (NYSEMKT:ONVO), Cubist ...  Techsonian (press release)
Related articles »  
Better Buy: Cubist Pharmaceuticals, Inc. vs. Durata Therapeutics, Inc.
Given the bipolar nature of regulatory decisions for biotechs, it's key to understand the risks relative to rewards associated with a company ahead of the event. With that in mind, here is a Foolish comparison of two biotechs, Cubist Pharmaceuticals ...
Cubist Appoints Robert J. Perez to Board of Directors
From 1987 to 1995, Mr. Perez held various sales and marketing positions at Zeneca Pharmaceuticals. Mr. Perez is a Director at AMAG Pharmaceuticals, Inc. and from 2006 - 2009 served as a Director at EPIX Pharmaceuticals, Inc. He is also a Trustee of the ...
Related articles »  
News Recap - TherapeuticsMD Inc (NYSEMKT:TXMD), Alnylam ...
Cubist Pharmaceuticals Inc (NASDAQ:CBST) reported 1.50 million shares were exchanged during the last trade, while the average volume is about 794,229 shares.
Related articles »  
Cubist Pharmaceuticals Given �Buy� Rating at Aegis (CBST)
Cubist Pharmaceuticals Inc logo Cubist Pharmaceuticals (NASDAQ:CBST)'s stock had its �buy� rating reiterated by analysts at Aegis in a research report issued to clients and investors on Tuesday, Analyst Ratings Network reports.
RSI Alert: Cubist Pharmaceuticals (CBST) Now Oversold
In trading on Monday, shares of Cubist Pharmaceuticals Cubist Pharmaceuticals Inc. (NASD: CBST) entered into oversold territory, hitting an RSI reading of 29.2, after changing hands as low as $65.76 per share.
Related articles »  
Cubist Pharmaceuticals Rating Reiterated by Aegis (CBST)
Cubist Pharmaceuticals Inc logo Cubist Pharmaceuticals (NASDAQ:CBST)'s stock had its �buy� rating reaffirmed by equities research analysts at Aegis in a research note issued to investors on Tuesday, American Banking and Market News reports.
Cubist Pharmaceuticals PT Raised to $73.00 at Cantor Fitzgerald (CBST)  Ticker Report
Stocks Cheers on Upbeat Move: Target Corp. (TGT), UTi Worldwide Inc. (UTIW ...  Techsonian (press release)
Related articles »  
Why MannKind (MNKD) is Outpacing these Biotech Stocks, Questcor ...
Cubist Pharmaceuticals, Inc. (NASDAQ:CBST) shares moved up 2% after the company reported that it would issue its first quarter 2014 financial results at 4:00 p.m.
Related articles »  
Volatile Movements-Cubist Pharmaceuticals Inc (CBST), Microvision, Inc. (MVIS ...
Cubist Pharmaceuticals Inc (NASDAQ:CBST) decreased -4.97% and closed at $70.35 on a traded volume of 1.13 million shares, in comparison to 753,707.00 shares of average trading volume.